Standard BioTools

Standard BioTools Market capitalization

The The market capitalization of Standard BioTools (LAB) as of Oct 29, 2026 is 430.71 M USD. In the previous year, The market capitalization was 430.71 M USD — a change of 0.00% (lower).

Market capitalization

430.71 MUSD

YoY

0.00%

Last updated:

In 2025, Standard BioTools's market cap stood at 430.71 M USD, a 0.00% increase from the 430.71 M USD market cap in the previous year.

The Standard BioTools Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
430.71 M USD
Jan 1, 2019
430.71 M USD
Jan 1, 2020
430.71 M USD
Jan 1, 2021
430.71 M USD
Jan 1, 2022
430.71 M USD
Jan 1, 2023
430.71 M USD
Jan 1, 2024
430.71 M USD
Jan 1, 2025
430.71 M USD
The Standard BioTools Market capitalization history
YEARMarket capitalizationYoY
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD0.00%
430.71 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Standard BioTools's Market Capitalization

Standard BioTools's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Standard BioTools's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Standard BioTools's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Standard BioTools’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Standard BioTools stock

The market capitalization of Standard BioTools is 430.71 M USD in 2025.

The market capitalization of Standard BioTools changed from 430.71 M USD to 430.71 M USD, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Standard BioTools with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Standard BioTools

All Key Metrics — Standard BioTools